| 郑建津,刘雪瑜,郭露薇,蔡炳烨,戴小霞.益气宁心汤联合贝那普利治疗慢性心衰患者的临床疗效及对血清GDF-15、sST2、APN的影响[J].,2018,(16):3119-3122 |
| 益气宁心汤联合贝那普利治疗慢性心衰患者的临床疗效及对血清GDF-15、sST2、APN的影响 |
| Curative Efficacy of Yiqi Ningxin Decoction Combined with Benazepril in the Treatment of Chronic Heart Failure and Effects on the Serum GDF-15, sST2, APN Levels |
| 投稿时间：2017-10-26 修订日期：2017-11-21 |
| DOI：10.13241/j.cnki.pmb.2018.16.026 |
| 中文关键词: 益气宁心汤 贝那普利 慢性心衰 心功能 生长分化因子-15 可溶性ST2蛋白 脂联素 |
| 英文关键词: Yiqi Ningxin Decoction Benazepril Chronic heart failure Growth differentiation factor -15 Soluble ST2 protein Adiponectin |
| 基金项目: |
|
| 摘要点击次数: 574 |
| 全文下载次数: 259 |
| 中文摘要: |
| 摘要 目的：研究益气宁心汤联合贝那普利治疗慢性心衰患者的临床疗效及对血清生长分化因子-15(GDF-15)、可溶性ST2蛋白(sST2)、脂联素(APN)的影响。方法：收集2014年3月至2015年3月我院收治的80例慢性心衰患者，按抽签法分为实验组和对照组，每组40例。两组均给予常规基础对症治疗，对照组在此基础上加用贝那普利治疗，每次10 mg，每天1次，实验组在对照组的基础上加用益气宁心汤治疗，每天1剂，于早晚服用，两组治疗疗程均为2周。观察和比较两组的临床疗效及治疗前后心功能左心室舒张末径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)，GDF-15、sST2、APN水平、急性生理学与慢性健康状况评分(APACHE-Ⅱ)、肺部感染评分(CPIS)的变化。结果：治疗后，实验组总有效率显著高于对照组[92.50%(37/40) vs72.50%(29/40)](P＜0.05)；LVEDD、LVESD显著低于对照组[(53.56±6.24)mm vs(57.40±6.72)mm，(41.26±4.95)mm vs(46.28±4.86)mm](P＜0.05)，LVEF显著高于对照组[(57.91±5.93)% vs(50.27±5.90)%](P＜0.05)；血清GDF-15、sST2、APN水平显著低于对照组[(820.81±73.14)ng/L vs(1192.86±93.62)ng/L，(4.28±1.02)ng/mL vs(20.69±3.48)ng/mL，(13.47±2.18)mg/L vs(16.05±3.63)mg/L](P＜0.05)；APACHE-Ⅱ、CPIS评分显著低于对照组[(13.90±3.28)分 vs(20.37±4.97)分，(3.24±0.92)分 vs(5.38±1.01)分](P＜0.05)。结论：益气宁心汤联合贝那普利治疗慢性心力衰竭能显著提高其临床疗效，改善心心功能，可能与其有效降低血清GDF-15、sST2、APN的水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of Yiqi Ningxin Decoction combined with benazepril in the treatment of chronic heart failure and effects on the serum growth differentiation factor -15 (GDF-15), soluble ST2 protein (sST2), adiponectin (APN) levels. Methods: 80 cases of patients with chronic heart failure who were treated from March 2014 to March 2015 in our hospital were selected as research objects and divided into the control group and the experimental group according to the draw method, 40 cases in each group. Both groups were given routine basic symptomatic treatment. The control group was additionally treated by benazepril, 10mg every time, 1 time a day, while the experimental group was treated with Yiqi Ningxin Decoction on the basis of control group, 1 dose per day, once morning and evening. Both groups were treated for 2 weeks. Then the curative effect, changes of left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), DF-15, sST2, APN levels, acute physiology and chronic health evaluation scores (APACHE-II), pulmonary infection score before and after treatment were compared between two groups. Results: The total effective rate of experimental group was significantly higher than that of the control group[92.50%(37/40) vs 72.50%(29/40)](P＜0.05); the LVEDD, LVESD were significantly lower than the those of the control group[(53.56±6.24)mm vs (57.40±6.72)mm，(41.26±4.95)mm vs(46.28±4.86)mm](P＜0.05), the LVEF was significantly higher than that of the control group[(57.91±5.93)% vs (50.27±5.90)%](P＜0.05); the serum GDF-15, sST2 APN levels were significantly lower than those of the control group[(820.81±73.14)ng/L vs(1192.86±93.62)ng/L, (4.28±1.02)ng/mL vs(20.69±3.48)ng/mL, (13.47±2.18)mg/L vs(16.05±3.63)mg/L](P＜0.05); APACHE-Ⅱ, CPIS score were significantly lower than those of the control group[(13.90±3.28)score vs(20.37±4.97)score, (3.24±0.92)score vs(5.38±1.01)score](P＜0.05). Conclusion: Yiqi Ningxin Decoction combined with benazepril could enhance the clinical efficacy of chronic heart failure, it could improve the heart function, which might be ralted to the reduction of serum GDF-15, sST2, APN levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
